With over 100 therapeutic monoclonal antibodies and antibody based products in the market, the demand for developing and manufacturing of such products is anticipated to increase beyond the capabilities of innovator companies alone. Roots Analysis has announced the addition of the Antibody Contract Manufacturing Market, 2020-2030 report to its list of offerings. Although biopharmaceuticals offer significant profit margins and have been proven to be effective in treating a myriad of diseases, they are generally associated with high costs of development and complex manufacturing protocols; this is true for antibody based products as well. Presently, there are a number of companies that claim to offer end to end solutions, ranging from antibody development to commercial production. Further, prevalent trends suggest that sponsor companies are likely to continue relying on contract service providers for various aspects of antibody based product development and manufacturing.